Reagents, Instrumentation and Application Expertise Expected to Help Drive Development of New Therapies
BOSTON, MA -- March 27, 2006 – PerkinElmer Inc. (NYSE: PKI), a global leader in Health Sciences and Photonics, today announced that it has entered a collaborative agreement with the National Institute of Health’s National Chemical Genomics Center (NCGC) to provide reagents, instrumentation and scientific support for identifying small molecules, which can be valuable tools for understanding important cellular events involved in health and disease, potentially leading to drug discovery.
As part of the collaboration, NCGC gains access to PerkinElmer’s extensive reagent portfolio and scientific experts who are helping develop assays and protocols. The three leading reagent technologies being used are AlphaScreen™, LANCE™ and DELFIA™. AlphaScreen is an extremely sensitive non-radioactive homogeneous bead-based technology that allows the screening of a wide range of biological interactions, particularly with the largest target class – kinases. LANCE is a robust homogeneous technology that supports the measurement of various analytes and screens diverse biological interactions. DELFIA, the heterogeneous counterpart to LANCE, is an enabling time-resolved fluorescence technology allowing for sensitive and multiplexed detection of analytes.
“We are very pleased to be partnering with NCGC to help accelerate their chemical genomics efforts,” said Robert F. Friel, president, PerkinElmer Life and Analytical Sciences. “We believe that our capability to provide comprehensive solutions helps eliminate the time consuming and expensive problem of trying to unify all the components of drug discovery – liquid handling and prep, assay development and multilabel detection.”
About the NCGC and the NIH Roadmap Initiative
The NCGC is an ultrahigh-throughput screening and chemistry center which discovers chemical probes of gene and cell functions across the genome using its quantitative HTS (qHTS) technology, and develops new paradigms for screening that enable chemical genomics and downstream drug development. Located within the National Human Genome Research Institute as part of the National Institute of Health (NIH) Roadmap, all of the NCGC’s results are made freely available via PubChem (http://pubchem.ncbi.nlm.nih.gov). NIH Roadmap for Medical research is a series of far-reaching initiatives designed to transform the Nation’s medical research capabilities and speed the movement of scientific discoveries from the bench to the bedside. It provides a framework of the priorities the NIH must address in order to optimize its entire research portfolio and lays out a vision for a more efficient and productive system of medical research. Additional information about the NCGC can be found at http://www.ncgc.nih.gov, about the NIH Roadmap at http://nihroadmap.nih.gov , and about the NIH at http://www.nih.gov/.
Factors Affecting Future Performance
This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers’ demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) economic, political and other risks associated with foreign operations; (11) our ability to retain key personnel; (12) restrictions in our credit agreement; (13) our ability to realize the full value of our intangible assets; and (14) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
Other Information
Health Sciences end markets include genetic screening, environmental, service, biopharma, and medical imaging. Photonics markets include sensors and specialty lighting.